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Abstract
Background: Septic shock has a 90-day mortality risk of up to 50 %. The hemodynamic targets, including mean
arterial pressure (MAP) are not based on robust clinical data. Both severe hypotension and high doses of
vasopressors may be harmful. Hence, re-evaluation of hemodynamic targets in septic shock is relevant.
Methods/design: The targeted tissue perfusion versus macrocirculation-guided standard care in patients with
septic shock (TARTARE-2S) trial is a prospective, two-parallel-group, randomized, open-label, multicenter trial with
assessor-blinded outcome evaluation. We will randomize at least 200 patients with septic shock in four European
intensive care units (ICUs) to test whether a tissue perfusion-guided treatment strategy based on capillary refill time,
peripheral temperature, arterial lactate concentrations, and accepting lower MAP levels, leads to a faster resolution
of shock than macrocirculation target-guided standard care.
The primary outcome measure is days alive in 30 days with normal arterial blood lactate (first value of <2 mmol/L)
and without any inotropic or vasopressor agent. Secondary outcomes include individual components of the
primary outcome, days alive without renal replacement, days alive without mechanical ventilation in 30 days, and
new acute kidney injury. The sample size enables detection of a 13.5-h difference in the primary outcome with a
type 1 error of 5 % and power of 80 %, assuming 25 % mortality and a mean of 650 h (SD 30) among the 30-day
survivors. After 150 included patients the statistician masked for allocation group will recalculate the sample size
potentially increasing the sample up to 300. The Data Safety and Monitoring Board (DSMB) will review the safety
data after 100 patients.
Discussion: The TARTARE-2S trial will provide important clinical data on treatment targets in septic shock,
evaluating the impact of clinical tissue perfusion-guided hemodynamic treatment on a surrogate outcome
combining resolution of shock (hyperlactatemia and vasopressors/inotropes), and 30-day mortality.
Trial registration: ClinicalTrials.gov: NCT02579525. Registered on 19 October 2015.
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Background
Septic shock affects millions of people annually and has
a 90-day mortality rate of 18 to 50 % [1–5] depending
on the patient population and study selection criteria.
Early hemodynamic resuscitation and stabilization is
considered to be crucial for improved survival. Current
resuscitation strategies aim to achieve hemodynamic
stabilization as early as possible in order to prevent sub-
sequent organ dysfunction. The guidelines for initial
hemodynamic resuscitation of septic shock use primarily
macrocirculatory targets, such as mean arterial blood
pressure (MAP) and central venous pressure (CVP), and
surrogate markers of tissue perfusion such as diuresis.
Attempts to use central venous or mixed venous oxygen
saturation (ScVO2, SvO2) to guide resuscitation have
been disappointing. Despite early enthusiasm based
on a small single-center trial which suggested a major
improvement in survival [6], no benefit of ScVO2-
guided treatment was found in three large multicenter
trials [1, 4, 5].
The current SSC guidelines (Surviving Sepsis Cam-
paign: International Guidelines for Management of
Severe Sepsis and Septic Shock: 2012) [7] still
emphasize a MAP target and to a lesser extent tissue
perfusion. Systemic blood pressure and flow and
microcirculatory blood flow do not correlate well in
septic shock. This is especially true if systemic blood
pressure is achieved with vasoconstrictive drugs which
per se may impair microcirculation and clinical out-
come [8]. Furthermore, a recent systematic review [9]
underscored the paucity of clinical evidence to guide
the use of vasopressors and to support the current
recommendations regarding MAP target levels. In
summary, the current resuscitation guidelines for
septic shock might direct physicians to use higher
doses of vasopressors and inotropes and, thus, facili-
tate iatrogenic aggravation of shock-induced tissue
hypoperfusion.
Impaired tissue perfusion and microcirculation are
considered to be hallmarks of septic shock, and in-
creased arterial blood lactate in septic shock is a
marker of poor prognosis. These concepts provide a
rationale for therapeutic strategies focusing more on
improvement of tissue perfusion than systemic
hemodynamics. Normalization of elevated blood lac-
tate levels has been proposed to guide resuscitation in
septic shock because it may reflect tissue perfusion
during shock resuscitation better than strategies based
mainly on macrohemodynamic targets. The duration
of elevated lactate levels is a clinically relevant surro-
gate endpoint previously related to robust patient-
related adverse outcomes, such as multiple organ
dysfunction [10] and mortality [11, 12]. In addition,
lactate is also associated with peripheral perfusion
[13], and has been used as a target in a previous
large study in septic shock in comparison to ScVO2-
targeted therapy [14]. Abnormal peripheral perfusion,
defined as arm-to-fingertip temperature gradient of
>4 °C, and capillary refill time (CRT) >4.5 s), is asso-
ciated with multiple organ dysfunction in critically ill
patients [15] and with impaired tissue oxygen satur-
ation and poor outcome in septic shock patients [16].
Of note, subjectively assessed warmness of the per-
ipheral skin has good agreement with the measured
temperature differences [15]. The mottling score [17],
reflecting perfusion of the knee skin area, has also
been used. Additionally, biomarkers (to be explored
in sub-studies) indicating endothelial or cardiac dam-
age could elucidate the potential mechanisms leading
to untoward clinical patient-related outcomes, such as
septic acute kidney injury (AKI) [18] treated with
renal replacement therapy (RRT) [19], multiple organ
dysfunction, and death.
Aim
The objective is to compare the feasibility and the effect
of resolution of shock of two approaches to the man-
agement of tissue hypoperfusion in septic shock: (1)
targeted tissue perfusion (TTP) approach versus (2)
macrocirculation-guided (MCG) care – the latter
reflecting recommended standard care.
Methods/design
This trial is a prospective, investigator-initiated, multi-
center, two-parallel-group, randomized, open-label,
multicenter trial of TTP versus MCG care in patients
with septic shock (Appendix 1) with adequate gener-
ation of allocation sequence, and adequate allocation
concealment. Patients will be stratified by center and
by the presence/absence of chronic hypertension.
Each participating unit will go through an educational
program regarding study monitoring methods (includ-
ing CRT), and study reporting methods (including re-
peated hemodynamic target assessments and treatment
attempts).
The recruitment begins after approval from local
ethics committees.
Ethics committee approvals submission/approval
Bern University Hospital Ethics Committee (Kantonal
Ethiko Kommittee (KEK) Bern) 19 October 2015/22
March 2016.
Helsinki University Hospital Operative Ethics Com-
mittee – 23 October 2015/16 December 2015.
Rigshospitalet Ethics Committee – April 2016/
pending.
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Hypothesis
We hypothesize that targeting clinical tissue perfusion
(the TTP arm) will decrease the use and untoward
effects of vasopressors, and result in more days alive
in 30 days with normal arterial blood lactate (first
value of <2 mmol/L) and without any inotropic or
vasopressor agent – compared to standard clinical
care with preference of macrocirculatory targets (the
MCG arm).
Trial interventions
All patients will be treated according to the targets
(Appendix 2) of the allocated arm:
1. Intervention group – targeted tissue perfusion
(TTP) care
2. Control group – macrocirculatory targets-guided
(MCG) standard care
All interventions in both groups will be given at the
discretion of the treating clinicians according to the
targets. Both the hemodynamic problems detected
and the given interventions will be registered at each
change of treatment over time (Appendices 3 and 4).
Concomitant interventions
Treatment of septic shock is complex with multiple in-
terventions [6] and, as blinding of treating personnel is
not feasible, the use of several concomitant interventions
may be influenced by the allocated intervention arm. In
order to minimize these potential differences, treatment
suggestions for the following interventions will be
provided:
 Vasopressors – norepinephrine highly
recommended (the hemodynamic
problems to be registered and reported –
Appendix 3)
 Fluids – correction of hypovolemia
(preferably crystalloids, starch not to be used)
will be at the discretion of the treating clinician
(Appendix 3)
 Avoidance of excess fluids after 6 h from
randomization (amount of given fluids and
balance over time up to 72 h will be registered
and reported)
 Inotropic agents – to increase impaired flow,
dobutamine is preferred – if ineffective, adrenaline
may be used
 Glucocorticoids – recommended not to
be used
 Blood products – red blood cell (RBC)
transfusion trigger 70 g/L, unless ischemia or
active bleeding [2]
 Renal replacement therapy (RRT) –
suggested criteria according to conventional
standard criteria [19, 20], with proven feasibility
[21] as follows:
(a)serum potassium ≥6.0 mmol/L, or
(b)pH <7.20 and serum bicarbonate
≤10 mmol/L, or
(c)evidence of severe respiratory failure, based on a
PaO2/FiO2 < 200 and clinical perception of volume
overload and oliguria, or
(d)persistent severe AKI (serum creatinine
remains >50 % the value recorded at
randomization) for more than 72 h from
randomization
 Lung-protective ventilation – positive end-
expiratory pressure (PEEP) ≥5 cmH2O, tidal volume
<8 ml/ideal body weight, and plateau pressure <30
cmH2O
Inclusion criteria
Septic shock defined as (Appendix 1):
1. Infection (suspected or documented) and
2. Systemic mean blood pressure above 65 mmHg
requiring any dose of vasopressors (norepinephrine,
epinephrine, vasopressin) despite adequate fluid
resuscitation (minimum of 20 ml/kg (actual body
weight) crystalloids) and
3. Elevated lactate ≥3.0 mmol/L with suspected
hypoperfusion
Exclusion criteria
 Age below 18 or over 80 years
 Any other probable condition than sepsis affecting
or expected to affect the central nervous system,
including post cardiac arrest
 Myocardial ischemia
 Acute pulmonary embolism
 Terminal illness and not considered for full intensive
care support
 Use of extra-corporeal membrane oxygenation
(ECMO)
 Known liver disease – Child-Pugh classes B or C
 Known chronic kidney disease
 Known to be pregnant or lactating
 More than 4 h from fulfilled inclusion criteria (to be
fullfilled at the latest 4 hours after ICU admission)
to randomization (to be done in 8 hours from ICU
admission)
 Other probable cause of hyperlactatemia
 Patients transferred from another intensive care unit
(ICU)
 Patients with active hematological malignancy
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Randomization
Randomization will be done using a computer-based
algorithm created by an independent statistician, to
allow immediate and concealed allocation to the
intervention arm. The patients will be stratified ac-
cording to the site and presence/absence of chronic
hypertension (with known medication). A varying
block size will be used. Each patient will be allocated
a unique patient ID-number. Randomization is tar-
geted to be performed within 2 h after fulfillment of
the inclusion criteria in the ICU (but no later than
4 h, the fulfillment of which is an exclusion
criterion).
Primary outcome measure
 Days alive in 30 days – with normal
arterial blood lactate (first confirmed value
of <2 mmol/L and without any inotropic or
vasopressor agent)
Secondary outcome measures
1. Time to normalization of lactate
2. Days alive with normal lactate (all values <2 mmol/
L) in 30 days
3. Days alive without the use of inotropic or
vasopressor agents in 30 days
4. Days alive without RRT in 30 days
5. Days alive without mechanical ventilation in
30 days
6. Days alive without any organ support (mechanical
ventilation, RRT) in 30 days
7. New AKI according to the KDIGO classification
(stages I–III)
8. 8.. Days alive outside hospital in 90 days
9. Total amount of norepinephrine given until
day 5
10.Number/total number of the following adverse
reactions:
(a)ventricular tachycardia/fibrillation
(b)atrial fibrillation
(c)myocardial infarction
(d)skin necrosis
(e)stroke
(f ) secondary bowel ischemia
(g)limb ischemia
(h)total numbers of serious adverse
reactions (SAR) (numbers of patients
and reactions)
Exploratory outcomes
All-cause mortality at day 90.
Blinding
Blinding of health care providers will not be feasible
which infers that all clinical staff caring for the patients
will be aware of the allocation during the intervention
period. The two interventions may lead to different use
of concomitant interventions, but the lack of blinding
may also result in differences in the use of concomitant
interventions during the intervention period. Hence, we
will provide suggestions for the use of relevant co-
interventions (see “Concomitant interventions”) and will
record the use of them.
Information on the primary outcome and other sec-
ondary outcomes will be provided by the local investi-
gators from patient charts, but the statistician doing
the analyses will be blinded to which intervention the
patients received. Information on whether the ex-
ploratory outcome of death occurs will be acquired
through public registers (the National Civil Registries)
without knowledge of which intervention group the
patient was allocated to. In Switzerland, the patient
or relatives will be contacted. The assessor of the out-
comes will be blinded to the study group. The mem-
bers of DSMB will remain blinded unless they request
otherwise.
Participant discontinuation and withdrawal
Patients who are withdrawn from the trial protocol will
be followed up and analyzed as the remaining patients
(intention-to-treat analysis, ITT).
Suspension of the protocol
The protocol may temporarily be suspended for the indi-
vidual patient, at the discretion of the treating clinicians,
if the patient is to be resuscitated in the presence of any
acute condition superimposed on septic shock, as judged
by the investigator. Patients to be operated on at op-
erational theatres may also have their procedures sus-
pended during that time.
Severe adverse reactions (SARs)
SARs to norepinephrine:
1. Cerebral hemorrhage seen on computed
tomography (CT) or magnetic resonance imaging
(MRI) scan
2. Cardiac arrhythmia resulting in the use of
medication or electrical cardioversion
3. Psychiatric symptoms resulting in the use of
antipsychotic drugs
Not registered as SARs to norepinephrine: tremor,
headache, dizziness, and sweats are not registered.
Hypertension is not registered. Dyspnea itself is not
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regarded as a serious adverse event (SAE). Hypersaliva-
tion, nausea, and vomiting are not registered.
SAEs will not be recorded as an entity, because the
majority of septic ICU patients will experience several
SAEs during their critical illness. The most important
SAEs will be captured in the secondary outcome mea-
sures and in the daily Sequential Organ Failure As-
sessment (SOFA)-scoring. Patient charts will contain
daily registrations of detailed clinical data, which can
be obtained on request from the medical authorities.
Trial investigators are to report suspected unexpected
serious adverse reactions (SUSARs) without undue
delay to the chief investigators, which in turn will re-
port these to the Swiss, Finnish and Danish Health
and Medicine Authorities within 7 days after the re-
port has been received.
Statistical plan and data analysis
Sample size and power
We assume 25 % mortality in both study groups, and
this phase II trial will be unlikely to have the power to
detect any mortality difference between the intervention
groups. Therefore, a surrogate endpoint (days alive in
30 days with normal lactate and without vasopressors)
combining survival, need for vasopressor therapy, and
normalization of hyperlactatemia has been chosen. A
post-hoc analysis from the FINNAKI study in a similar
study population revealed a 30-day mortality rate of
25 %, and in 98 patients (of 128) who survived the mean
time alive without vasopressors or hyperlactatemia
within 30 days (720 h) was 650 h (SD 35) (unpublished
data).
In the power analysis we assumed that the time with
vasopressors or hyperlactatemia among the 30-day survi-
vors follow a log-normal distribution with mean of 70 h
(70 minus “treatment effect among survivors for the
TTP group”) and SD 30, this simulated value was sub-
tracted from 720 h (the number of hours in 30 days).
For each configuration of sample size, mortality rate and
expected treatment effect we simulated data and com-
pared the two groups using a Mann-Whitney test. Ten
thousand simulations were done for each configuration
to compute the power. The required sample sizes (both
groups combined) to achieve 80 % power as a function
of mortality proportion (i.e., fraction of patients with a
zero value for the primary endpoint) and average change
in the primary endpoint among survivors are displayed
in Table 1.
The clinically relevant difference in the study pri-
mary outcome to be tested is 18 h (Amendment 1
to the study protocol – 26 October 2015). An adap-
tive sample size adjustment will be employed. After
150 patients have been included and followed for
30 days, the study statistician (Assoc. Professor T.
Lange, University of Copenhagen) will redo the
power calculation based on the observed mortality
proportion and the observed dispersion in the pri-
mary outcome. The calculation will be done with-
out un-blinding the study and will follow the
previous recommendation by Chow and Chang
(based on the revised power calculation a sugges-
tion for a revised sample size will be presented to
the investigators) (https://www.crcpress.com/Adaptive-
Design-Methods-in-Clinical-Trials-Second-Edition/Chow-
Chang/9781439839874).
Statistical methods
The study flowchart is included as Fig. 1. A Mann-
Whitney test for differences in continuous outcomes
including the primary outcome measure, and Fisher’s
exact test for dichotomous variables will be done as
a primary analysis. A sensitivity analysis in sub-
groups of patients with and without previous hyper-
tension will be performed. The components of the
primary outcome measure (time to normalization of
lactate, time to stopping of all vasoactive drugs, and
day-30 mortality) are all included among secondary
outcomes. In all tests a p value of less than 0.05 will
be considered statistically significant. If missing data
are >5 %, multiple imputations will be performed. A
detailed statistical analysis plan is provided in
Appendix 5.
Table 1 Power calculations
Change among survivors in hours (and among all patients)
Mortality proportion 12 h (9 h) 18 h (13.5 h) 24 h (18 h)
20 % 340 156 90
25 % 438 194 118
30 % 562 270 158
35 % 660 348 210
40 % 660 456 282
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Interim analysis
As this trial is a feasibility trial we do not consider an in-
terim analysis appropriate. As an interim analysis will
not be performed, statistical early stopping criteria will
not be applied. However, the Data Safety and Monitoring
Board (DSMB) has full access to the safety data and will
do a thorough review of these after 100 patients, and
may recommend stopping the study anytime based on
safety concerns.
Intervention accountability
Every patient will be allocated a registration sheet to
be kept in the site master file. The initials, birth date,
screening number, time for randomization, and study
arm will be included. The compliance of trial arm
targets for each study patient will be checked hourly
for the first 72 h, and clinical problems and given
hemodynamic treatments will be registered until the
study combined endpoint has been fulfilled, up to day
30. The originals for these documents will be kept as
the study source data at each site.
Registration
ClinicalTrials.gov: NCT02579525 (Registration date 19
October 2015).
Data to be registered
The continuous data on hemodynamic parameters
will be registered as 10-min medians using electronic
PMDS, when possible and otherwise registered each
hour to 72 h. For other data please see “Appendix 4.”
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) figure regarding study
interventions and timing is provided as Fig. 2.
Data handling
Data will be entered into an electronic, web-based
electronic Case Report Form (eCRF) from patient
notes by trial personnel. Each patient will receive a
unique trial identification number. Trial investigators
will receive a personal username and passwords to
access the TARTARE-2S trial web-page. Each site
will only have access to site-specific data. Data will
Fig. 1 The TARTARE-2S study flowchart
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be handled according to the Swiss, Finnish and
Danish laws. All original records (including Informed
Consent Forms, eCRFs, and relevant correspon-
dences) will be archived at trial sites for 15 years.
The clean electronic trial database file will be deliv-
ered to the Inselspital Data Archive and maintained
for 15 years and anonymized, if requested by the
authorities.
Monitoring
The trial will be externally monitored (Clinical Trial
Unit, Bern) to Good Clinical Practice (GCP) standards.
A centralized day-to-day monitoring of the eCRF will be
done by the coordinating investigator.
Ethical considerations
In addition to fluid therapy, norepinephrine administra-
tion to increase the MAP is a key element in the treat-
ment of septic shock. As the intervention is very
frequent, but not evidence-based and carries potential
risks, we consider it to be in the wider interests of soci-
ety and patients to perform research in this area, as
clearly highlighted in a recent systematic review and
meta-analysis [9]. The present trial is a phase II trial,
i.e., a trial assessing both the feasibility of the proto-
col in a clinical setting and a patient-centered surro-
gate outcome. Should the trial prove feasible with
separation between the two interventions, and suggest
a benefit in terms of the primary endpoint, a larger
phase III trial assessing 90-day mortality is intended.
Thus, it is the opinion of the Steering Committee
that this study is very important and ethically
justified.
In some retrospective observational studies, low MAP
has been associated with an increased risk of acute
kidney injury (AKI) [22–24]. However, causal infer-
ences cannot be drawn from observational data with
the inherent limitation that the most severely ill
Fig. 2 The schedule of enrollment, interventions, and assessments
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patients inevitably have lower MAPs. In the present
study: (1) a minimum safety limit of MAP has been
set to the TTP group, (2) the study patients are care-
fully monitored and re-evaluated, and treatment goals
are registered every hour. In addition, (3) the treating
clinician should allow lower MAP values only in
situations without any clinical problems, such as
oliguria, in which cases individual use of higher
MAP targets is allowed (and also in previously
hypertensive patients). Thus, the Steering Committee
has strong reasons to believe that the care of the
study patients will be better and safer than the
highly varying standard clinical practice; e.g., regard-
ing fluid treatment [25]. In addition, high-quality
randomized controlled trials (RCTs) focusing on un-
proven but widely used standard treatments have
been shown to change clinical practice and to save
future critically ill patients from untoward adverse
events and death, e.g., by avoiding the use of starch
in septic shock [26].
Treatment of septic shock is time-dependent and
many patients will be unconscious and, due to fever
and/or septic brain dysfunction, unable to consider
an informed consent. Inclusion of only conscious
less severely ill patients would cause a significant
bias and jeopardize the study results. Furthermore,
the treatment separation and effect are plausibly
most obvious the earlier the randomization occurs.
Of note, both treatment arms are within the frame
of current standard clinical practice and no investi-
gational drugs are used, thus, ethically allowing the
potential use of a deferred consent. Therefore,
patients will be included either with a deferred con-
sent, or a proxy consent (next of kin) according to
national laws in Finland, Switzerland, and Denmark
(two-physician consent also allowed in Denmark).
The patient or next of kin and/or general practi-
tioner will be asked for a deferred consent if
required by national law.
The trial will adhere to the trial protocol, the
Helsinki Declaration in its latest form, GCP guide-
lines, and the national laws in the countries involved.
Inclusion will start after approval by the ethics com-
mittees, medicines agencies, data protection agencies,
and health authorities in the countries of the trial
sites.
Informed consent
The process leading to obtaining informed consent
will be in compliance with all applicable regulations
and national laws. Patients with septic shock are sel-
dom able to consider their consent due to fever,
mechanical ventilation, sedation, and/or septic en-
cephalopathy. However, those patients who regain
consciousness will be asked for informed consent as
soon as possible. The possible benefit of the treat-
ment (and the separation between the study arms)
will plausibly be larger the sooner the treatment is
started. In addition, it is important not to introduce a
significant bias to the study results by only including
less severely ill patients because most plausibly the
most severely ill patients will benefit most. The con-
senting party will be provided with written and oral
information about the trial so they are able to make
an informed decision about participation in the trial.
Written information and the consent form will be
subjected to review and approval by the National
Ethics Committee.
Duration
For clinical treatment, primary and secondary end-
point up to 30 days; follow-up exploratory endpoint
until day 90.
Co-enrollment
Possible simultaneous co-enrollment to any other
RCT will be discussed by the Management
Committee.
Timeline
Trial sites determined – September 2015
Governance approval applications submitted –
October 2015
First participant enrolled – April 2016
Last participant enrolled – November 2017
Follow-up completed – December 2017
Data analysis and submission for the main
publication – March 2018
Laboratory analyses completed – June 2018
Publications of clinical sub-studies and laboratory
analyses completed – December 2018
Trial organization
Steering Committee
Ville Pettilä, Helsinki University Hospital, and Inselspital,
Bern (CI1)
Jukka Takala, Inselspital, Bern, Switzerland (CI2)
Stephan Jakob, Inselspital, Bern, Switzerland
Anders Perner, Copenhagen University Hospital,
Rigshospitalet, Denmark.
Site principal investigators (PIs)
Tobias Merz, Inselspital, Bern
Erika Wilkman, Helsinki University Hospital
Sari Karlsson, Tampere University Hospital
Anders Perner, Rigshospitalet, Copenhagen
Pettilä et al. Trials  (2016) 17:384 Page 8 of 13
Data Safety and Monitoring Board (DSMB)
Professor Konrad Reinhart (chair), Jena
Professor Peter Jüni, Bern/Toronto
Professor Jan Wernerman, Stockholm
Independent statistician
Assoc. Professor Theis Lange, Centre for Research in
Intensive Care and Section of Biostatistics, University of
Copenhagen.
Trial sponsors
The coordinating investigators, CI1 Ville Pettilä and CI2
Jukka Takala, are trial sponsors.
Laboratory measurements
Ethylenediaminetetraacetic acid (EDTA) plasma sam-
ples and whole blood will be drawn as soon as pos-
sible after ICU admission, and at 72 h from ICU
admission for later analysis of patient-related
changes in biomarkers indicating endothelial/myocar-
dial damage, such as CD73 and vascular adhesion
protein-1 (VAP-1), heparin-binding protein (HBP),
chromogranin A (CgA), metabolomics, and mitochondrial
function tests.
Publication plan
All trial results whether positive, negative, or neutral
will end up in the public domain, preferably in a
peer-reviewed publication. All trial sites with at least
25 randomized patients will be granted one author-
ship for the site PI, and each additional 25 patients
will guarantee one additional authorship for the site
AIs. A trial statistician (TL) will also be granted an
authorship. The order of authorships for the study
main publication will be as follows: VP, SJ, and AP
will be the first, second, and third, and JT the last
author. Other authors will be in the order of in-
cluded number of patients with high-quality data:
site PIs first, and AIs thereafter. The authorships for
the publications of the main and sub-studies will fol-
low the International Committee of Medical Journals
Editors’ (ICMJE) principles. The full protocol and
the participant-level anonymized dataset will be
submitted as appendices with the main paper to be
publicly available after the study publication. The
SPIRIT checklist for clinical trial protocol is provided
as Additional file 1.
Perspectives
Septic shock affects millions of patients worldwide
annually. The results of study will – in any case –
have a major influence on the clinical management/
international guidelines regarding treatment of septic
shock. If supporting our hypothesis of the beneficial
effects of TTP, the current recommendations will
have to be changed leading to major scientific and
societal impacts on heath and health care costs. In
case MCG proves to be better, the study results will
for the first time confirm the widely recommended
minimum MAP level. Given that several different
pathophysiological pathways are probably in inter-
action and may only partly explain the clinical
course of the disease, the potential strength of meas-
uring several biomarkers/mitochondrial function/
gene expression and protein synthesis in the sub-studies
of this phase II study, will give us the opportunity to com-
pare their relative importance and predictive power with
regard to organ dysfunction.
Discussion
Conduct of the TARTARE-2S trial is in broad agree-
ment with the international guidelines [7] regarding
the control group. The targeted patient population
fulfills the recent Sepsis-3 septic shock definition
[27], representing the most severely ill septic shock
patients with plausibly the highest possible chance to
show a difference between the intervention arms
[28], if such a difference exists. The experimental
approach is supported by a recent review [9]
highlighting the paucity of evidence to support the
guidelines and additional evidence suggesting the
relevance of more detailed monitoring of peripheral
perfusion [13, 14] to guide the treatment in septic
shock. The TARTARE-2S trial may be one of the
first trials to bridge the gap between evidence and
clinical practice and to provide detailed data on efficacy
and safety of TTP to guide treatment in patients with
septic shock.
Trial status
Patient recruitment has started in May 2016. Ethics and
hospital approvals have been granted in Finland, and in
Switzerland, and have been applied in Denmark (as of
July 28, 2016).
Appendix 1 The trial criteria for septic shock
Septic shock is defined as:
1. Infection (suspected or documented) and
2. Systemic mean blood pressure above 65 mmHg
requiring any dose of vasopressors (norepinephrine,
vasopressin) despite adequate fluid resuscitation
(minimum of 20 ml/kg (actual body weight)
crystalloids) and
3. Elevated lactate ≥3.0 mmol/L with suspected
hypoperfusion
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Appendix 2 Appendix 3
Appendix 4 Data to be registered
Data will be obtained in eCRFs from a combination of
national registers and medical records. Bedside target list
for treatment reasons and decisions will be implemented
in the PDMS (*) at each site, if possible.
Baseline variables
 National identification number (if available)
 Sex
 Age at randomization
 Estimated height
 Measured (if not possible estimated) weight
 Comorbidities? Y/N (hypertension*, chronic heart
failure*, previous myocardial infarction, previous
stroke, chronic obstructive pulmonary disease*,
diabetes*, hematological malignancy*, metastatic
cancer*, AIDS*)
 Elective or emergency admission*
 Operative or non-operative admission*
Table 2 The trial targets for the treatment arms. (Register
hourly up to 24 h (every 2 h thereafter until study endpoint
using tick boxes for targets)
I. Intervention group – targeted tissue perfusion (TTP) care:
Primary targets
Capillary refill time (CRT)/
every hour
<3 s
Skin mottling [17]/every
hour
Absent
Peripheral temperature/
every hour
Warm
Urine output/every hour ≥0.5 mL/kg/h
Arterial lactate [7]/per 2 h <2.0 mmol/L
Mean arterial pressure (MAP) 50–65 mmHg (minimum as a safety limit)
aIf previous hypertension [7] a65–70 mmHg
bIf oliguria <0.3 ml/kg [7] b2-h trial 75–80 mmHg,
If diuresis improves, continue for 2 h and
re-evaluate
Secondary target
Continuous SvO2 [7], if
available
>65 %c
II. Control group – macrocirculatory targets-guided (MCG) standard care
Primary targets
Mean arterial pressure (MAP)
[7]
65–75 mmHg
aIf previous hypertension [7] a75–80 mmHg
bIf oliguria <0.3 ml/kg b2-h trial 85–90 mmHg
If diuresis better, continue for 2 h and
re-evaluate
Central venous pressure
(CVP) [7]
8–12 mmHg
Adequate fluid therapy is indicated to
restore clinical hypovolemia up to the
recommended CVP level of 8–12 mmHg,
if needed
Urine output [7] ≥0.5 mL/kg/h
Secondary target
Continuous SvO2 [7], if
available
>65 %c
Dellinger et al. [7] according to the SSCG – Surviving Sepsis Campaign
Guidelines: MAP, CVP, diuresis, SvO2 – 1C, lactate – 2C (1 – a recommendation,
2 – a suggestion, C – low level of evidence)
aHigher MAP targets may be required for septic shock patients with previous
hypertension; band a test of providing higher MAP target for 2 h is
recommended for those with oliguria
bThe treating physicians should target to the lowest possible vasopressor use
to maintain the highlighted lowest possible MAP level in each treatment arm;
however, allowing individual higher MAP targets with specific reasons
cMeasuring of ScVO2 is not recommended [1, 4, 5]. If monitoring is clinically
required, use of a pulmonary artery catheter (PAC) is recommended. Pulse
continuous cardiac output (PICCO) may be used for thermodilution cardiac
output measurements
Table 3 Data to be gathered regarding each hemodynamic
target and treatment decision/change. Indicate when treatment
start or change (at the same time)
(a). Hemodynamic problem(s)
Hemodynamic problem(s) Tick
Hypovolemia
Hypervolemia
Inadequate flow/cardiac index (CI)
Tachycardia
Inadequate contractility
Inadequate afterload/hypotension
Excessive afterload/hypertension
Excessive vasopressor dose
(b). Given treatment(s)
Treatment(s) given Tick
Volume
Diuretics
Inotrope
Inotrope decrease
Inotrope increase
Vasopressor increase
Vasopressor decrease
Beta-blocking agent
Vasodilating agent
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 Site of infection (pulmonary/abdominal/urinary
tract/soft tissue/other)
 Previous plasma/serum creatinine (7–365 days
before hospital admission), if available
24-h from ICU admission:
 Values for Simplified Acute Physiology Score (SAPS II)*
Twenty-four hours before randomization
 Volume of resuscitation fluids (crystalloids, colloids
and blood products specified in milliliters)
 Hemoglobin (lowest)*
 SOFA score variables*
At randomization
 Norepinephrine dose and mean arterial pressure
(MAP) at the same time
 Total fluids given in last 2 h
 Lactate (last value from the previous 2 h)
Continuously as 10-min medians in the first 72 h after
randomization:
 Systolic arterial pressure*
 Mean arterial pressure*
 Central venous pressure*
 Heart rate*
 Peripheral oxygen saturation (SpO2)*
 Continuous central venous oxygen saturation, if
available
 Continuous mixed venous saturation, if available
 Dose of norepinephrine*
 Dose of dobutamine*
One-hour intervals (for 72 h)
 Urinary output*
 Volume of given fluids
 CRT – only in the TTP group
 Assessment of upper arm temperature – only in the
TTP group
 Assessment of skin mottling score – only in the
TTP group
Two-hour intervals (for 72 h unless study endpoint
reached)
 Arterial lactate measured in both groups
Four-hour intervals during the first 72 h after
randomization (if not discharged from the ICU)
 Arterial blood gas tensions (PaO2, PaCO2), pH and
base excess (BE)
 Calculated Mixed v-aCO2/Da-vO2-ratio (if pulmon-
ary artery catheter, PAC)
 Cardiac index (if PAC)
 Stroke index (if PAC)
Daily in the first 7 days after randomization (if not dis-
charged from the hospital):
 SOFA score variables*
 Total volume of fluids
 Estimated fluid balance
 Dose of glucocorticoids (not recommended)
Daily up to 30 days:
 On mechanical invasive- or non-invasive ventila-
tion? Y/N
 Ventilator settings at 8 a.m. (PEEP, Pplat, Vt)
 Use of muscle relaxants during the last 24 h? Y/N
 Presence of acute kidney injury (AKI) according to
KDIGO classification? Y/N/and stage (I–III)
 Use of renal replacement therapy? Y/N
 Use of vasopressors? Y/N
 Use of inotropic agents? Y/N
 Ischemic events
 SARs and SUSARs
Appendix 5 A detailed study statistical analysis
plan
The primary analysis of the primary outcome (as well as
secondary outcomes b, c, d, e, f, h, i, and j) will be an
unadjusted Mann-Whitney test. As a sensitivity analysis
the p values will be recalculated using permutations
within groups defined by site and the presence/absence
of hypertension. This test is a non-parametric version of
an ANOVA adjusted for site and presence/absence of
hypertension. A total of 100,000 permutations will be
conducted for each test. The effect sizes will be quanti-
fied by direct comparisons of the raw means between
groups. Confidence intervals will determined by non-
parametric bootstrapping to accommodate the highly
non-normal distribution of the outcomes.
The secondary endpoint “a” will be assessed by a Cox
model treating death before normalization of lactate as a
competing event. The Cox model will be adjusted for
site and presence/absence of hypertension. The effect
size will be quantified using the adjusted hazard ratio.
The secondary outcome “g” will be assessed using
Fisher’s exact test. Effect sizes will be analyzed using
crude proportions along with standard normality
approximation-based confidence intervals.
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The exploratory endpoint (90-day survival) will be
assessed using Fisher’s exact test. Effect sizes will be
quantified using odds ratios from a logistic regression
adjusted for site and the presence of hypertension. As a
sensitivity analysis a Cox model of time to death will
also be employed. The Cox model will be adjusted for
site and the presence/absence of hypertension. Here, the
effect size will be quantified using the adjusted hazard
ratio. The assumption of proportional hazards will be
assessed using Schoenfeld residuals. Finally, Kaplan-
Meier plots will be produced.
If any of the tests presented above must be based on
data with more than 5 % missing multiple imputation
will be employed. If just one test needs to be based on
multiple imputation all tests will be conducted both as
complete case analysis and multiple imputation. How-
ever, only for tests based on data with more than 5 %
missing will the multiple imputation approach constitute
the primary analysis. The multiple imputation will be
conducted in R using the mice package and the recom-
mendation in accordance with recommendations in the
documentation of this package. All outcome variables
(secondary and primary), sex, and age as well as stratifi-
cation and treatment variables will be included in the
multiple imputations procedure.
In all tests a p value of less than 0.05 will be consid-
ered statistically significant. It is noted that as the adap-
tive sample size recalculation is not depended on a
particular value of the treatment effect at the time of re-
calculation, there is accordingly no need to adjust the
significance level to take a possible adjustment of sample
size into account. All analyses will be conducted in the
statistical software package R. The full statistical analysis
will be conducted blinded to actual treatment allocation
and a full blinded statistical report produced. Of note,
un-blinding will first happen after the full statistical
report has been finalized.
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